Repligen Corp. Stock
Repligen Corp. Stock
The price for the Repligen Corp. stock decreased slightly today. Compared to yesterday there is a change of -€1.100 (-0.780%).
With 21 Buy predictions and not a single Sell prediction Repligen Corp. is an absolute favorite of our community.
With a target price of 151 € there is a slightly positive potential of 5.74% for Repligen Corp. compared to the current price of 142.8 €.
So far the community has only identified positive things for Repligen Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Repligen Corp. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | -0.780% | 9.888% | 13.019% | 48.133% | 1.384% | -9.045% | -32.800% |
| Opko Health Inc. | 0.850% | 5.357% | 3.509% | 9.158% | 8.237% | -26.953% | -62.540% |
| China Traditional Chinese Medicine Co Ltd | 0.000% | 0.000% | 0.000% | -5.983% | 0.917% | -37.500% | -50.450% |
| Viatris Inc. | 0.590% | -8.397% | -1.839% | 61.240% | 32.757% | 34.818% | 9.815% |
Comments
Repligen (RGEN) was upgraded by Zacks Research from "hold" to "strong-buy".
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target raised by Wells Fargo & Company from $180.00 to $185.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target raised by JPMorgan Chase & Co. from $165.00 to $175.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat